1. Home
  2. OBIO vs RFI Comparison

OBIO vs RFI Comparison

Compare OBIO & RFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • RFI
  • Stock Information
  • Founded
  • OBIO 2017
  • RFI 1992
  • Country
  • OBIO United States
  • RFI United States
  • Employees
  • OBIO N/A
  • RFI N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • RFI Investment Managers
  • Sector
  • OBIO Health Care
  • RFI Finance
  • Exchange
  • OBIO Nasdaq
  • RFI Nasdaq
  • Market Cap
  • OBIO 291.7M
  • RFI 299.4M
  • IPO Year
  • OBIO N/A
  • RFI N/A
  • Fundamental
  • Price
  • OBIO $8.03
  • RFI $11.94
  • Analyst Decision
  • OBIO Strong Buy
  • RFI
  • Analyst Count
  • OBIO 2
  • RFI 0
  • Target Price
  • OBIO $17.00
  • RFI N/A
  • AVG Volume (30 Days)
  • OBIO 249.9K
  • RFI 69.8K
  • Earning Date
  • OBIO 08-08-2024
  • RFI 01-01-0001
  • Dividend Yield
  • OBIO N/A
  • RFI 8.25%
  • EPS Growth
  • OBIO N/A
  • RFI N/A
  • EPS
  • OBIO N/A
  • RFI N/A
  • Revenue
  • OBIO $2,216,000.00
  • RFI N/A
  • Revenue This Year
  • OBIO $17.90
  • RFI N/A
  • Revenue Next Year
  • OBIO $10.51
  • RFI N/A
  • P/E Ratio
  • OBIO N/A
  • RFI N/A
  • Revenue Growth
  • OBIO N/A
  • RFI N/A
  • 52 Week Low
  • OBIO $4.22
  • RFI $9.62
  • 52 Week High
  • OBIO $11.69
  • RFI $12.52
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 54.75
  • RFI 60.84
  • Support Level
  • OBIO $7.80
  • RFI $11.56
  • Resistance Level
  • OBIO $8.87
  • RFI $12.21
  • Average True Range (ATR)
  • OBIO 0.60
  • RFI 0.19
  • MACD
  • OBIO -0.01
  • RFI 0.03
  • Stochastic Oscillator
  • OBIO 59.02
  • RFI 64.47

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

Share on Social Networks: